Breaking News
December 15, 2017 - Researchers identify potential alternatives to tackle drug resistant malaria parasites
December 15, 2017 - Scientists unravel mystery of how immune cells remember infections decades later
December 15, 2017 - Outcomes Poorer for Black Patients with Early Breast Ca
December 15, 2017 - Liposuction May Ease Limb Swelling in Cancer Patients
December 15, 2017 - How well can digital assistants answer questions on sex?
December 15, 2017 - NIH-funded study to explore hearing loss risk in Detroit firefighters
December 15, 2017 - Caris Life Sciences reveals identification of new mechanism of action to treat NHL
December 15, 2017 - Loyola Medicine study finds high success rate for diabetic Charcot foot surgery
December 15, 2017 - Bone marrow edema does not increase due to intense physical activity, study finds
December 15, 2017 - Human ‘common cold’ virus kills healthy chimpanzees in Uganda
December 15, 2017 - Experience of reflex walking refines perception of biological motion during early infancy
December 15, 2017 - FDA Approves Admelog (insulin lispro) Rapid-Acting “Follow-On” Insulin Product to Treat Diabetes
December 14, 2017 - Friday Feedback: Good Idea for Ex-Pharma Exec to Run HHS?
December 14, 2017 - More than 200 people sickened onboard Ovation of Seas cruise
December 14, 2017 - FDA announces new approach for sharing updates on antibiotics, antifungal drugs to physicians
December 14, 2017 - Steroid study provides new insights into medicines’ side effects
December 14, 2017 - Government announces plans to include eye test reminder during driving license renewal
December 14, 2017 - Non-ionizing radiation from magnetic fields could have adverse biological impacts on health
December 14, 2017 - Bi-annual MRI beats mammograms in detecting breast cancer among women with genetic risk
December 14, 2017 - Researchers develop new method for quickly detecting signs of multiple sclerosis
December 14, 2017 - In era of increased competition, hospitals fret over ratings
December 14, 2017 - Female veterans experience improvement in low back pain with course of chiropractic care
December 14, 2017 - Relieving Symptoms of Cystic Fibrosis with Exercise
December 14, 2017 - FDA Alert: Blue Pearl All Natural Male Enhancement Supplement: Recall
December 14, 2017 - CardioBrief: In Defense Of ORBITA
December 14, 2017 - Definition of High Blood Pressure Drops: MedlinePlus Health News
December 14, 2017 - Drug may help surgical patients stop opioids sooner
December 14, 2017 - Researchers develop biosensor that enables development of new health tests
December 14, 2017 - Radiation therapy can be used to treat patients with life-threatening heart rhythm
December 14, 2017 - UVA researchers developing tool to help prostate cancer patients weigh treatment options
December 14, 2017 - Experts tell Congress how to cut drug prices
December 14, 2017 - Researchers use cryptographic techniques to decode activity of motor neurons
December 14, 2017 - Study finds changes in the heart after spinal cord injury
December 14, 2017 - Health Highlights: Dec. 12, 2017
December 14, 2017 - Pelzman’s Picks: How States Can Cut Disparities in Care and Costs
December 14, 2017 - New Hemophilia Treatment Stems Bleeding Episodes: MedlinePlus Health News
December 14, 2017 - Onetime ‘world’s heaviest man’ has second surgery in Mexico
December 14, 2017 - Belgian researchers create transplantable artificial ovary prototype
December 14, 2017 - Using atraumatic needles for lumbar punctures decreases risk of complications
December 14, 2017 - Outpatient total knee replacement surgery linked to higher rates of complications
December 14, 2017 - Social impairments can be corrected by brain stimulation
December 14, 2017 - Studies reveal possibility for memory T cells to serve a dual purpose
December 14, 2017 - Antibody-Drug Conjugate Ups PFS in Untreated Hodgkin’s
December 14, 2017 - Study finds reading information aloud to yourself improves memory
December 14, 2017 - Researchers use RNA nanotechnology to program exosomes for delivering effective cancer therapies
December 14, 2017 - Living Lyme disease bacteria found months after antibiotic treatment
December 14, 2017 - These annual checkups help seniors not only survive but thrive
December 14, 2017 - Study reveals impact of diabetes during pregnancy on baby’s heart
December 14, 2017 - Hydraulic fracturing is harmful to infants health, study states
December 14, 2017 - Huntington’s disease drug clears initial hurdles
December 14, 2017 - TPU researchers create 3D-printed models of children’s hearts
December 14, 2017 - Brain responses of children with inherited dyslexia risk predict their future reading speed
December 14, 2017 - People diagnosed with schizophrenia or bipolar disorder may actually have treatable condition
December 14, 2017 - Study: New Furosemide Formulation Simplifies Administration for HF
December 14, 2017 - Discrimination harms your health—and your partner’s
December 14, 2017 - Having older brothers may increase the likelihood of being gay
December 14, 2017 - New scientific yardstick released to help early detection of Alzheimer’s disease
December 14, 2017 - New finding demonstrates what happens at cellular level during onset of type2 diabetes
December 14, 2017 - Study identifies potassium as key to circadian rhythms in red blood cells
December 14, 2017 - Good friends might be your best brain booster as you age
December 14, 2017 - NIH expected to award up to $70 million to launch Alzheimer’s Clinical Trials Consortium
December 14, 2017 - Pitting pathogens against each other could prevent drug resistance emerging
December 14, 2017 - Study provides new insights into development of Sonic Hedgehog medulloblastoma
December 14, 2017 - Dr. Reddy’s Announces Approval of Impoyz (clobetasol propionate) Cream for Plaque Psoriasis
December 14, 2017 - Gene Screens Can Alter Perception, Behavior
December 14, 2017 - Can Scrotal Vein Condition Hike Heart Risks?: MedlinePlus Health News
December 14, 2017 - Molecules in spit may be able to diagnose and predict length of concussions
December 14, 2017 - Children’s Colorado and RxRevu partner to help prescribers better meet needs of pediatric patients
December 14, 2017 - Researchers discover new way to attack drug-resistant prostate cancer cells
December 14, 2017 - Scientists develop new, high resolution method for identifying microbial species and strains
December 14, 2017 - Declining trend of salmonellosis cases has leveled off in the EU
December 14, 2017 - Death receptors in the blood can help measure risk of cardiovascular diseases, type 2 diabetes
December 14, 2017 - How to Perk Up the Holidays for Hospital Patients
December 14, 2017 - Prolonged Sedation May be Bad for Baby’s Brain
December 14, 2017 - The pediatric submersion score predicts children at low risk for injury following submersions
December 14, 2017 - Video game helps doctors to quickly recognize trauma patients who need high levels of care
December 14, 2017 - Younger persons newly-diagnosed with type 2 diabetes have poorer health than older patients
December 14, 2017 - Clinician re-examines evidence on re-use of catheters and UTIs in people with spinal cord injuries
December 14, 2017 - UK and Russian researchers join forces against AMR
December 14, 2017 - Results of Bariatric Surgery Hold Up Over Time
Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia

Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia

image_pdfDownload PDFimage_print

NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for lumateperone for the treatment of schizophrenia. The Company requested Fast Track designation for lumateperone based on clinical evidence that lumateperone has the potential to address the unmet medical need for the treatment of schizophrenia with significant improvements on several clinically significant safety parameters, including with respect to metabolic, motor and cardiovascular issues associated with many currently available antipsychotic agents. The FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drug candidates to treat serious and life-threatening conditions. Fast Track designation may allow for more frequent meetings and communications with the FDA to discuss a drug candidate’s development plans and review process. Drug candidates with Fast Track designation may also qualify for priority review to expedite the FDA review process, if relevant criteria are met.

“We are pleased with the FDA’s designation of lumateperone for Fast Track development,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “Given the important safety and tolerability limitations of existing antipsychotics, we believe that lumateperone may represent a significant advance in the treatment of schizophrenia.”

About Schizophrenia

Schizophrenia is a chronic debilitating psychiatric disorder that affects over 1% of the world’s population. There remains a substantial unmet medical need for the treatment of schizophrenia. Existing treatments, while helpful for reducing the positive symptoms of schizophrenia, do not provide broad symptom control across other symptom domains and are limited in their use due to side effects that can include movement disorders, weight gain, metabolic disturbances, and cardiovascular abnormalities, all of which lead to poor medication adherence. Further, it has been demonstrated that poor adherence to antipsychotics is associated with higher risk of relapse, rehospitalization and increased healthcare costs.

About Lumateperone for the Treatment of Schizophrenia

Lumateperone, our lead product candidate, is a first-in-class molecule that provides selective and simultaneous modulation of serotonin, dopamine, and glutamate—three neurotransmitter pathways implicated in severe mental illness. Unlike existing schizophrenia treatments, lumateperone is a dopamine receptor phosphoprotein modulation, or DPPM, acting as a pre-synaptic partial agonist and post-synaptic antagonist at D2 receptors. We believe this mechanism, along with potent interactions at 5-HT2A receptors, serotonin transporters, and D1 receptors with indirect glutamatergic modulation, may contribute to the efficacy of lumateperone across a broad array of symptoms, with improved psychosocial function and favorable tolerability. This compound has the potential to benefit patients suffering from a range of neuropsychiatric and neurodegenerative diseases.

Our clinical development program for the treatment of schizophrenia with lumateperone includes three large randomized, double-blind, placebo-controlled trials. In two studies, ITI-007 60 mg showed a statistically significant separation from placebo on the primary endpoint, the Positive and Negative Syndrome Scale, or PANSS, total score. Across all three studies, ITI-007 was found to be well tolerated with a safety profile similar to placebo.

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson’s and Alzheimer’s disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer’s disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer’s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company’s PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with Parkinson’s disease.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, our belief that lumateperone has the potential to address an unmet medical need for the treatment of schizophrenia, the potential benefits of Fast Track designation to facilitate or accelerate the regulatory approval of lumateperone for the treatment of schizophrenia, including the potential for more frequent meetings with the FDA and the potential qualification of lumateperone for priority review, our belief that lumateperone may represent a significant advance in the treatment of schizophrenia, our beliefs about the limitations of existing treatments for schizophrenia, our beliefs about the mechanisms of action of ITI-007; our beliefs about the extent to which the results of our clinical trials to date support an NDA filing for lumateperone for the treatment of schizophrenia; our expectations regarding our timelines for submitting an NDA to the FDA for the treatment of schizophrenia; our belief that lumateperone, if approved, will be an attractive treatment option for schizophrenia; our beliefs about the potential uses and benefits of our drug product candidates; and development efforts and plans under the caption “About Intra-Cellular Therapies.” All such forward-looking statements are based on management’s present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to the following: our current and planned clinical trials, other studies for lumateperone, and our other product candidates may not be successful or may take longer and be more costly than anticipated; the Fast Track designation may not lead to an expedited development, review or approval process and does not increase the likelihood that lumateperone will receive regulatory approval; the Fast Track designation may be rescinded by the FDA if the designation is no longer supported by data emerging in the clinical trial process; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our proposals with respect to the regulatory path for our product candidates may not be acceptable to the FDA; our reliance on collaborative partners and other third parties for development of our product candidates; and the other risk factors detailed in our public filings with the Securities and Exchange Commission. All statements contained in this press release are made only as of the date of this press release, and we do not intend to update this information unless required by law.

Source: Intra-Cellular Therapies Inc.

Posted: November 2017

Tagged with:

About author

Related Articles